Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hightide Therapeutics Inc ( (HK:2511) ) has provided an announcement.
HighTide Therapeutics, Inc. has announced that its board of directors will convene on August 25, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will address the company’s financial performance and potentially influence its market positioning and stakeholder confidence.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapies for metabolic and digestive diseases. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 2,813,099
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$1.81B
For detailed information about 2511 stock, go to TipRanks’ Stock Analysis page.